More Randomization in Phase II Trials: Necessary but not Sufficient
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
More Randomization in Phase II Trials: Necessary but not Sufficient
Authors
Keywords
-
Journal
JNCI-Journal of the National Cancer Institute
Volume 103, Issue 14, Pages 1075-1077
Publisher
Oxford University Press (OUP)
Online
2011-06-28
DOI
10.1093/jnci/djr238
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply)
- (2011) G. Visani et al. HAEMATOLOGICA
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma
- (2011) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trials: A Long-term Investment With Promising Returns
- (2011) M. R. Sharma et al. JNCI-Journal of the National Cancer Institute
- NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma
- (2011) Christian Griffiths et al. LANCET ONCOLOGY
- Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- (2010) M. Reck et al. ANNALS OF ONCOLOGY
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) S. Aebi et al. ANNALS OF ONCOLOGY
- Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710
- (2010) B. L. Powell et al. BLOOD
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
- (2010) B. Coiffier et al. BLOOD
- The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
- (2010) L. Seymour et al. CLINICAL CANCER RESEARCH
- The Evolving Field of Tyrosine Kinase Inhibitors in the Treatment of Endocrine Tumors
- (2010) Lei Ye et al. ENDOCRINE REVIEWS
- Randomized Phase II Trials: Inevitable or Inadvisable?
- (2010) Hui K. Gan et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trials: Misleading and Unreliable
- (2010) David J. Stewart JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Error Rates in Single-Arm Versus Randomized Phase II Cancer Clinical Trials
- (2010) Hui Tang et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
- (2010) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
- (2010) Keith C Bible et al. LANCET ONCOLOGY
- FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma
- (2010) J. Summers et al. ONCOLOGIST
- Randomized Phase II Designs
- (2009) L. Rubinstein et al. CLINICAL CANCER RESEARCH
- Alternate Endpoints for Screening Phase II Studies
- (2009) N. Dhani et al. CLINICAL CANCER RESEARCH
- Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
- (2009) Kirk R. Schultz et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation of novel imaging methodologies for use as cancer clinical trial end-points
- (2008) D.J. Sargent et al. EUROPEAN JOURNAL OF CANCER
- Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer
- (2008) Tomasz Burzykowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
- (2008) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- Exploring and validating surrogate endpoints in colorectal cancer
- (2008) Tomasz Burzykowski et al. LIFETIME DATA ANALYSIS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search